Whether anti-PLA2R antibody positivity can reliably exclude malignancy as the underlying cause in patients with membranous nephropathy (MN), evaluated through clinical outcomes after tumor treatment.
Anti-PLA2R positivity does not exclude malignancy-associated membranous nephropathy; some patients with detectable anti-PLA2R antibodies had remission of MN following tumor treatment, indicating a paraneoplastic etiology despite PLA2R seropositivity.
Likely a small case series or retrospective cohort, which limits generalizability; causality between tumor treatment and MN remission is difficult to establish definitively without controlled comparisons.
Clinicians should not use anti-PLA2R positivity alone to rule out cancer-associated membranous nephropathy — a thorough malignancy workup remains important even when PLA2R antibodies are detected.